OGT has been invited to present 'Role and significance of in vitro diagnostics in the healthcare systems of the future' at the British In Vitro Diagnostics Association (BIVDA) Trilateral Workshop.
Hosted at the French Embassy in Berlin on 16-17 June, the workshop will consist of a series of sessions and chaired discussions, presenting state-of-the-art research in in vitro diagnostics (IVD) applications.
On 17 June, Dr John Anson, vice president of biomarker discovery at OGT, will speak on 'Screening for novel oncology biomarker panels using both DNA and protein microarrays'.
Anson's presentation will explore how knowledge of the human genome and proteome can be used to design DNA and protein microarrays to screen for markers of cancers and autoimmune diseases.
He will also present the results from an internal study, demonstrating the ability to identify a set of biomarkers in serum samples that can distinguish between cancerous and non-cancerous prostate cells, with sensitivity and specificity levels above 90 per cent.
Such advances will lead to the generation of more accurate diagnostic tests with greater discriminatory power, offering improved patient outcomes.
